Posts Tagged ‘BSI-201’:

Triple unfavorable breast cancer: unmet medical needs

Pal SK, Childs BH, Pegram M. ” BREAST CANCER Analysis AND Therapy FEB 2011″ Triple negative breast cancer (TNBC) is surely an intense medical phenotype characterized by lack of expression (or minimal expression) of estrogen receptor (ER) and progesterone receptor (PR) as well as an absence of human epidermal growth issue receptor-2 (HER2) overexpression. It

(Read More…)

Tags:

Novel specific therapeutics: inhibitors of MDM2, ALK and PARP

Yuan, Y ; Liao, YM ; Hsueh, CT ; Mirshahidi, HR “JOURNAL OF HEMATOLOGY & ONCOLOGY 2011 Apr” We reviewed preclinical data and clinical development of MDM2 (murine double minute 2), ALK (anaplastic lymphoma kinase) and PARP (poly [ADP-ribose] polymerase) inhibitors. MDM2 binds to p53, and promotes degradation of p53 through ubiquitin-proteasome degradation. JNJ-26854165 and

(Read More…)

© Apoptosis|apoptosis inhibitor|apoptosis pathway
CyberChimps